Poseida Therapeutics Q2 EPS $(0.32) Beats $(0.41) Estimate, Sales $25.97M Beat $15.43M Estimate
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics (NASDAQ:PSTX) reported better-than-expected Q2 results with an EPS of $(0.32) beating the $(0.41) estimate and sales of $25.97M surpassing the $15.43M estimate. Sales increased by 29.78% year-over-year.
August 05, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics reported Q2 EPS of $(0.32), beating the $(0.41) estimate, and sales of $25.97M, surpassing the $15.43M estimate. Sales increased by 29.78% YoY.
The better-than-expected EPS and significant sales beat, along with a notable year-over-year sales increase, are likely to positively impact PSTX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100